+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Research Antibodies & Reagents Market by Type (Antibodies, Reagents), Source (Mouse-Derived, Rabbit-Derived, Rat-Derived), Technology, Disease Area, Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666480
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Research Antibodies & Reagents Market grew from USD 18.55 billion in 2024 to USD 20.79 billion in 2025. It is expected to continue growing at a CAGR of 12.00%, reaching USD 36.62 billion by 2030.

Setting the Stage for Antibodies and Reagents Research with a Comprehensive Overview of Market Dynamics and Emerging Opportunities for Decision Makers

The antibodies and reagents landscape has evolved dramatically over recent years driven by advances in biotechnology and growing demands in diagnostics, research and therapeutics. These molecular tools have become fundamental to breakthroughs in disease detection, immunotherapy and personalized medicine. The interplay between academic discovery and commercial development has accelerated innovation cycles, resulting in more targeted, high-affinity primary and recombinant antibodies as well as sophisticated detection reagents capable of single-cell resolution analysis.

As research complexity increases, end users across academic institutions, biopharmaceutical companies and contract research organizations are seeking solutions that offer reproducibility at scale and precise performance metrics. This trend has propelled investments into robust production platforms and modular reagent kits, facilitating seamless integration into diverse workflows. Meanwhile regulatory scrutiny and quality standards are shaping product development pathways and market access strategies.

Moreover, emerging applications in genomics, proteomics and cell-based assays are redefining the scope of antibody and reagent utility, creating new avenues for discovery as well as novel therapeutics. By synthesizing recent technological breakthroughs with evolving user requirements and policy landscapes, this introduction frames the context for a comprehensive exploration of market transformation, tariff impacts, segmentation patterns and regional dynamics.

Against this backdrop, research stakeholders must navigate a complex web of supply chain disruptions, intellectual property considerations and competitive positioning in a landscape that rewards agility and strategic foresight. This summary sets the stage for an in-depth examination of transformative shifts, tariff landscape impacts, segmentation insights, regional dynamics, leading companies and actionable guidance for industry leaders seeking to capitalize on emerging opportunities

Exploring the Transformative Shifts Innovations in Antibody Production Reagent Development and Regulatory Landscapes That Are Reshaping Research Priorities

Over the past decade, the antibodies and reagents sector has witnessed transformative shifts driven by breakthroughs in molecular engineering, automation and computational analytics. The advent of phage display and hybridoma optimization techniques has enabled the rapid development of recombinant antibodies with enhanced specificity and stability. Concurrently, advanced detection reagents leveraging fluorescence, chemiluminescence and mass spectrometry are offering unparalleled sensitivity for both qualitative and quantitative assays. These technological advances are reshaping workflows, reducing time to result and permitting high-throughput screening at scales previously unattainable.

Regulatory frameworks have also evolved in parallel, adapting to encompass novel biologics and companion diagnostics. Streamlined approval pathways for in vitro diagnostic components, coupled with heightened emphasis on reproducibility and traceability, are influencing product design and vendor selection. Digitalization is another key driver, with integrated laboratory information management systems and cloud-based data repositories enabling seamless sample tracking and real-time data analysis. Machine learning algorithms are now being applied to predict antibody-antigen interactions, optimizing reagent selection for complex assays. Together, these shifts underscore a broader industry transition toward precision research tools that align with the demands of personalized medicine and targeted therapeutic development

Assessing the Cumulative Impact of 2025 United States Tariffs on Antibodies and Reagents Supply Chains Research Collaborations and Cost Structures

Since the introduction of expanded United States tariffs in 2025, the antibodies and reagents ecosystem has adapted to a recalibrated cost structure and supply chain topology. Tariffs imposed on imported raw materials, cell culture components and finished antibody products have prompted manufacturers and end users to reassess sourcing strategies. Many global suppliers have explored tariff mitigation by expanding domestic production facilities, forging joint ventures with local biotechnology firms and adjusting regional distribution networks. These realignments have improved supply chain resilience but have also necessitated investment in regulatory compliance and quality assurance across multiple jurisdictions.

In addition, research organizations have diversified supplier portfolios to balance cost pressures against performance requirements, often integrating reagent alternatives from emerging domestic producers. Collaborative consortia have formed to share best practices and negotiate procurement agreements. Meanwhile, pricing strategies have been revisited to reflect the incremental duties and logistical overheads while maintaining competitiveness. As research budgets tighten and operational efficiencies are prioritized, the industry is witnessing a strategic shift toward lean manufacturing, on-demand production and modular reagent platforms designed to minimize inventory risk and maximize flexibility in the face of evolving trade policies

Uncovering Key Segmentation Insights Across Type Source Technology Disease Area and Application to Illuminate Market Dynamics and Customer Needs

In analyzing the market through multiple segmentation lenses, distinct patterns emerge that illuminate the intricate dynamics of the antibodies and reagents domain. When considering type, antibodies and reagents represent the foundational categories, with antibodies further subdivided into primary variants-including monoclonal and polyclonal classes-as well as recombinant and secondary formats, each tailored to specific affinity and application requirements. Reagents encompass a broad spectrum, ranging from buffers and solutions, cell culture reagents, cytokines and growth factors, detection reagents, enzymes, fixatives and stains, nucleic acids, probes, proteins and peptides to vectors and plasmids, reflecting the diverse operational needs of modern laboratories.

Assessing the market by source highlights the prominence of mouse-derived, rabbit-derived and rat-derived antibodies, each offering unique advantages in terms of epitope recognition, binding kinetics and cross-reactivity profiles. Technological segmentation reveals that enzyme-linked immunosorbent assay platforms, both competitive and sandwich formats, remain a workhorse for quantitative analysis, while flow cytometry, immunofluorescence, immunohistochemistry, immunoprecipitation, lateral flow assays, mass spectrometry and western blotting each contribute distinct functional capabilities to the research toolkit. Further segmentation by disease area underscores the critical role of these products in cardiology research addressing atherosclerosis and hypertension, infectious disease investigations targeting bacterial and viral pathogens, neurology studies focused on Alzheimer’s and Parkinson’s disease, and oncology research directed at breast and lung cancer. Finally, application and end user segmentation illustrate the breadth of utilization-from diagnostic and therapeutic development contexts to genomics and proteomics research conducted within academic institutions, biopharmaceutical companies and contract research organizations-providing a granular perspective on market demands and innovation drivers

Illuminating Key Regional Insights Spanning the Americas Europe Middle East Africa and Asia Pacific to Guide Strategic Investments and Collaborative Efforts

A regional analysis uncovers heterogeneous trends across the Americas, Europe Middle East and Africa, and Asia-Pacific regions. In the Americas, strong research and development investment, particularly within the United States, has fueled demand for high-performance antibodies and reagents across academic, clinical and commercial settings. Collaborative networks foster technology transfer and innovation hubs, while favorable regulatory initiatives support expedited pathways for diagnostic reagent approval and clinical assay validation. Latin American markets are emerging as key growth areas, leveraging regional partnerships to bolster local production capabilities and reduce reliance on imports.

Within Europe Middle East and Africa, the landscape is defined by regulatory harmonization efforts across the European Union, alongside divergent approval processes in Middle Eastern and African nations. Established biotechnology clusters in Western Europe continue to drive cutting-edge reagent applications in personalized medicine, while emerging markets in North Africa and the Gulf Cooperation Council countries are investing in local research infrastructure and strategic alliances. Supply chain decentralization and harmonized quality standards are critical for meeting diverse clinical and research requirements across this broad region.

Asia-Pacific dynamics are characterized by rapid expansion in China, India and Southeast Asian nations, where government-sponsored initiatives are accelerating biopharmaceutical innovation and domestic reagent manufacturing. The region’s focus on cost-effective production, combined with robust academic collaboration, has led to a proliferation of reagents optimized for regional disease burdens and research priorities. Strategic partnerships between global suppliers and local firms are enhancing market access and enabling tailored solutions that address specific regulatory frameworks and end user needs

Highlighting Key Industry Players Innovations Strategic Partnerships and Competitive Positioning Shaping the Antibodies and Reagents Market Landscape

The competitive landscape in the antibodies and reagents domain is shaped by leading industry players that drive innovation through strategic collaborations, targeted acquisitions and robust product pipelines. Established global suppliers have invested heavily in next-generation antibody platforms, offering recombinant and bispecific formats, high-throughput screening services and integrated assay development solutions. These firms leverage expansive research networks and state-of-the-art manufacturing facilities to deliver consistent performance metrics and global distribution capabilities.

Emerging biotechnology enterprises are carving niche positions by focusing on specialized applications such as single-cell omics, advanced flow cytometry reagents and novel detection chemistries. They often partner with academic institutions to accelerate early-stage development and validation of proprietary reagents. Contract research organizations and reagent distributors are also pivotal, providing customized assay development, scaling services and region-specific logistical support. This collaborative ecosystem enhances agility, enabling rapid responses to evolving research demands and regulatory shifts.

Mergers and acquisitions continue to redefine market positioning, with large players integrating innovative start-ups to access cutting-edge technologies and expand their application portfolios. Co-development agreements between reagent manufacturers and diagnostic equipment vendors are driving seamless platform integrations, while licensing partnerships facilitate the cross-pollination of antibody libraries and reagent chemistries. Collectively, these strategic moves underscore the dynamic and interconnected nature of competition within the antibodies and reagents market

Presenting Actionable Recommendations to Accelerate Innovation Navigate Trade Dynamics and Strengthen Antibody and Reagent Supply Chains for Industry Leaders

Industry leaders seeking to capitalize on emerging opportunities must adopt a multifaceted approach that balances innovation with operational excellence. It is essential to invest in advanced molecular engineering capabilities-such as phage display, next-generation sequencing-driven antibody discovery and artificial intelligence-powered binding prediction-to remain at the forefront of antibody development. Simultaneously, optimizing manufacturing processes through lean methodologies and modular reagent platforms can reduce lead times and enhance scalability in response to fluctuating demand.

Strategic diversification of supply chains will mitigate exposure to trade policy volatility, particularly in the context of evolving tariff landscapes. Collaboration with regional production partners and the establishment of onshore or nearshore manufacturing sites can preserve continuity of supply while ensuring regulatory compliance. Engaging proactively with regulatory agencies to align product specifications and validation protocols will streamline approval pathways for diagnostic and therapeutic reagents.

Finally, fostering cross-sector partnerships-involving biopharmaceutical developers, academic research centers and contract research organizations-will accelerate translational research and unlock new application areas. Emphasizing sustainability through green chemistry practices, reduced waste generation and energy-efficient manufacturing will not only address environmental imperatives but also resonate with stakeholders prioritizing corporate responsibility. By integrating these recommendations, industry leaders can strengthen their competitive positioning and drive sustained growth in the antibodies and reagents market

Detailing the Research Methodology Employed to Ensure Data Integrity Comprehensive Analysis and Actionable Insights in Antibody and Reagent Market Studies

This research was conducted using a multilayered methodology designed to ensure comprehensive coverage and data integrity. Initially, in-depth secondary research drew upon peer-reviewed literature, regulatory filings, patent databases and scientific conference proceedings to establish a foundational understanding of current technologies and market drivers. This phase included systematic reviews of technical publications and white papers, as well as analysis of industry reports to identify emerging trends and key regulatory developments.

Primary research followed, involving structured interviews with key opinion leaders, senior executives at biopharmaceutical firms, academic researchers and procurement specialists. These interviews provided qualitative insights into adoption barriers, supply chain challenges and technology roadmaps. Data obtained from both primary and secondary sources were triangulated to validate findings, with discrepancies addressed through follow-up discussions and cross verification against public disclosures.

Quantitative analysis incorporated data modeling of trade flow statistics, reagent inventories and patent filing trends, augmented by time-series evaluation of regulatory approval timelines. Expert panels reviewed preliminary findings to ensure methodological rigor and domain relevance. All research activities adhered to ethical standards for data collection and confidentiality, culminating in a robust framework that supports actionable strategic guidance for stakeholders across the antibodies and reagents landscape

Summarizing the Core Findings Implications and Strategic Considerations for Stakeholders Navigating the Dynamic Antibody and Reagent Research Landscape

In conclusion, the antibodies and reagents market stands at a pivotal juncture, shaped by rapid technological advancements, evolving regulatory frameworks and the recalibration of global trade policies. The integration of recombinant antibody platforms, advanced detection chemistries and digital analytics is redefining research and diagnostic capabilities, while the imposition of new tariff regimes has spurred supply chain realignment and domestic manufacturing initiatives. Segmentation analysis reveals nuanced demand patterns across type, source, technology, disease area and end user, underscoring the importance of tailored product development and strategic partnerships.

Regional insights demonstrate that market dynamics vary significantly across the Americas, Europe Middle East and Africa and Asia Pacific, necessitating localized approaches to regulatory compliance, logistical infrastructure and collaboration models. Competitive positioning is increasingly influenced by mergers and acquisitions, technology licensing and co-development agreements that accelerate innovation and expand application portfolios. Looking ahead, industry leaders will need to embrace agile manufacturing, diversified sourcing and sustainable practices to navigate ongoing uncertainties and capture future growth opportunities. The strategic considerations outlined herein provide a comprehensive foundation for decision makers aiming to leverage antibodies and reagents as catalysts for scientific discovery and therapeutic innovation

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Type
    • Antibodies
      • Primary Antibodies
        • Monoclonal Antibodies
        • Polyclonal Antibodies
      • Recombinant Antibodies
      • Secondary Antibodies
    • Reagents
      • Buffers & Solutions
      • Cell Culture Reagents
      • Cytokines & Growth Factors
      • Detection Reagents
      • Enzymes
      • Fixatives & Stains
      • Nucleic Acids
      • Probes
      • Proteins & Peptides
      • Vectors & Plasmids
  • Source
    • Mouse-Derived
    • Rabbit-Derived
    • Rat-Derived
  • Technology
    • Enzyme-Linked Immunosorbent Assay
      • Competitive Assays
      • Sandwich Assays
    • Flow Cytometry
    • Immunofluorescence
    • Immunohistochemistry
    • Immunoprecipitation
    • Lateral Flow Assays
    • Mass Spectrometry
    • Western Blotting
  • Disease Area
    • Cardiology
      • Atherosclerosis
      • Hypertension
    • Infectious Diseases
      • Bacterial Infections
      • Viral Infections
    • Neurology
      • Alzheimer's Disease
      • Parkinson's Disease
    • Oncology
      • Breast Cancer
      • Lung Cancer
  • Application
    • Diagnostic
    • Drug Development
    • Research & Development
      • Genomics
      • Proteomics
    • Therapeutics
  • End User
    • Academic Research Institutions
    • Biopharmaceutical Companies
    • Contract Research Organizations
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Alpha Teknova, Inc.
  • Atlas Antibodies AB
  • Avantor, Inc.
  • BASF SE
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMérieux S.A.
  • Cardinal Health, Inc.
  • Cell Signaling Technology, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Dovetail Genomics LLC
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • FUJIFILM Holdings Corporation
  • GenScript Biotech Corporation
  • Honeywell International Inc.
  • Illumia, Inc.
  • ImmunoPrecise Antibodies Ltd.
  • Leinco Technologies, Inc.
  • LifeSpan BioSciences, Inc.
  • LobaChemie Pvt. Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Omega Bio-tek, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Randox Laboratories Ltd.
  • Rockland Immunochemicals, Inc.
  • Santa Cruz Biotechnology, Inc.
  • Sino Biological, Inc.
  • Thermo Fisher Scientific, Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Tosoh Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of recombinant antibodies and phage display technologies for enhanced specificity and batch consistency
5.2. Integration of single-cell proteomics reagents in immunology workflows for high-resolution cellular analysis
5.3. Emergence of synthetic antibody fragments (nanobodies) as versatile tools for diagnostic and therapeutic applications
5.4. Expansion of multiplex immunoassay reagent kits for simultaneous detection of multiple biomarkers in clinical trials
5.5. Regulatory scrutiny and quality standard harmonization influencing antibody validation and reagent manufacturing processes
5.6. Custom antibody development services leveraging AI-driven epitope mapping for faster lead identification cycles
5.7. Growth of bioorthogonal labeling reagents for real-time tracking of protein dynamics in live-cell imaging platforms
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Research Antibodies & Reagents Market, by Type
8.1. Introduction
8.2. Antibodies
8.2.1. Primary Antibodies
8.2.1.1. Monoclonal Antibodies
8.2.1.2. Polyclonal Antibodies
8.2.2. Recombinant Antibodies
8.2.3. Secondary Antibodies
8.3. Reagents
8.3.1. Buffers & Solutions
8.3.2. Cell Culture Reagents
8.3.3. Cytokines & Growth Factors
8.3.4. Detection Reagents
8.3.5. Enzymes
8.3.6. Fixatives & Stains
8.3.7. Nucleic Acids
8.3.8. Probes
8.3.9. Proteins & Peptides
8.3.10. Vectors & Plasmids
9. Research Antibodies & Reagents Market, by Source
9.1. Introduction
9.2. Mouse-Derived
9.3. Rabbit-Derived
9.4. Rat-Derived
10. Research Antibodies & Reagents Market, by Technology
10.1. Introduction
10.2. Enzyme-Linked Immunosorbent Assay
10.2.1. Competitive Assays
10.2.2. Sandwich Assays
10.3. Flow Cytometry
10.4. Immunofluorescence
10.5. Immunohistochemistry
10.6. Immunoprecipitation
10.7. Lateral Flow Assays
10.8. Mass Spectrometry
10.9. Western Blotting
11. Research Antibodies & Reagents Market, by Disease Area
11.1. Introduction
11.2. Cardiology
11.2.1. Atherosclerosis
11.2.2. Hypertension
11.3. Infectious Diseases
11.3.1. Bacterial Infections
11.3.2. Viral Infections
11.4. Neurology
11.4.1. Alzheimer's Disease
11.4.2. Parkinson's Disease
11.5. Oncology
11.5.1. Breast Cancer
11.5.2. Lung Cancer
12. Research Antibodies & Reagents Market, by Application
12.1. Introduction
12.2. Diagnostic
12.3. Drug Development
12.4. Research & Development
12.4.1. Genomics
12.4.2. Proteomics
12.5. Therapeutics
13. Research Antibodies & Reagents Market, by End User
13.1. Introduction
13.2. Academic Research Institutions
13.3. Biopharmaceutical Companies
13.4. Contract Research Organizations
14. Americas Research Antibodies & Reagents Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Research Antibodies & Reagents Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Research Antibodies & Reagents Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. Agilent Technologies Inc.
17.3.3. Alpha Teknova, Inc.
17.3.4. Atlas Antibodies AB
17.3.5. Avantor, Inc.
17.3.6. BASF SE
17.3.7. Becton, Dickinson and Company
17.3.8. Bio-Rad Laboratories, Inc.
17.3.9. Bio-Techne Corporation
17.3.10. bioMérieux S.A.
17.3.11. Cardinal Health, Inc.
17.3.12. Cell Signaling Technology, Inc.
17.3.13. Charles River Laboratories International, Inc.
17.3.14. Danaher Corporation
17.3.15. Dovetail Genomics LLC
17.3.16. Enzo Life Sciences, Inc.
17.3.17. F. Hoffmann-La Roche Ltd.
17.3.18. FUJIFILM Holdings Corporation
17.3.19. GenScript Biotech Corporation
17.3.20. Honeywell International Inc.
17.3.21. Illumia, Inc.
17.3.22. ImmunoPrecise Antibodies Ltd.
17.3.23. Leinco Technologies, Inc.
17.3.24. LifeSpan BioSciences, Inc.
17.3.25. LobaChemie Pvt. Ltd.
17.3.26. Lonza Group Ltd.
17.3.27. Merck KGaA
17.3.28. Omega Bio-tek, Inc.
17.3.29. PerkinElmer, Inc.
17.3.30. QIAGEN N.V.
17.3.31. Randox Laboratories Ltd.
17.3.32. Rockland Immunochemicals, Inc.
17.3.33. Santa Cruz Biotechnology, Inc.
17.3.34. Sino Biological, Inc.
17.3.35. Thermo Fisher Scientific, Inc.
17.3.36. Tokyo Chemical Industry Co., Ltd.
17.3.37. Tosoh Corporation
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. RESEARCH ANTIBODIES & REAGENTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. RESEARCH ANTIBODIES & REAGENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. RESEARCH ANTIBODIES & REAGENTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. RESEARCH ANTIBODIES & REAGENTS MARKET: RESEARCHAI
FIGURE 28. RESEARCH ANTIBODIES & REAGENTS MARKET: RESEARCHSTATISTICS
FIGURE 29. RESEARCH ANTIBODIES & REAGENTS MARKET: RESEARCHCONTACTS
FIGURE 30. RESEARCH ANTIBODIES & REAGENTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RESEARCH ANTIBODIES & REAGENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RECOMBINANT ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RECOMBINANT ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SECONDARY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SECONDARY ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BUFFERS & SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BUFFERS & SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CELL CULTURE REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CELL CULTURE REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CYTOKINES & GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CYTOKINES & GROWTH FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DETECTION REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DETECTION REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY FIXATIVES & STAINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY FIXATIVES & STAINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROBES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROBES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROTEINS & PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROTEINS & PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY VECTORS & PLASMIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY VECTORS & PLASMIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MOUSE-DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MOUSE-DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RABBIT-DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RABBIT-DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RAT-DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RAT-DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COMPETITIVE ASSAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COMPETITIVE ASSAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SANDWICH ASSAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SANDWICH ASSAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOPRECIPITATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOPRECIPITATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY GENOMICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY GENOMICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROTEOMICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROTEOMICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 205. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 206. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 207. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 208. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 209. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 210. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 211. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
TABLE 212. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
TABLE 213. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 214. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 215. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 216. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 217. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 218. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 219. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
TABLE 220. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
TABLE 221. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
TABLE 222. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
TABLE 223. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 224. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 225. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 226. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 227. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 228. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 229. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 230. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 231. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 232. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 233. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 236. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 237. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 238. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 239. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 240. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 241. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
TABLE 242. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
TABLE 243. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 244. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 245. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 246. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 247. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 248. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 249. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
TABLE 250. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
TABLE 251. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
TABLE 252. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
TABLE 253. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 254. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 255. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 256. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 257. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 258. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 259. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 260. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 261. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 262. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 263. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA RESEARCH ANTIBOD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Research Antibodies & Reagents market report include:
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Alpha Teknova, Inc.
  • Atlas Antibodies AB
  • Avantor, Inc.
  • BASF SE
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMérieux S.A.
  • Cardinal Health, Inc.
  • Cell Signaling Technology, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Dovetail Genomics LLC
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • FUJIFILM Holdings Corporation
  • GenScript Biotech Corporation
  • Honeywell International Inc.
  • Illumia, Inc.
  • ImmunoPrecise Antibodies Ltd.
  • Leinco Technologies, Inc.
  • LifeSpan BioSciences, Inc.
  • LobaChemie Pvt. Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Omega Bio-tek, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Randox Laboratories Ltd.
  • Rockland Immunochemicals, Inc.
  • Santa Cruz Biotechnology, Inc.
  • Sino Biological, Inc.
  • Thermo Fisher Scientific, Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Tosoh Corporation

Table Information